Bishop B.M.,Summa Health System
American Journal of Therapeutics | Year: 2015
The role that low levels of high-density lipoprotein cholesterol (HDL-C) plays in coronary artery disease and ischemic heart disease is well established. As such, therapies targeting low HDL-C levels have been of great therapeutic interest. These therapies include nonpharmacological methods such as exercise, tobacco cessation, weight reduction, moderate alcohol intake, and increasing dietary monounsaturated fatty acids and polyunsaturated fatty acids. Additionally, pharmacological methods of increasing HDL-C have been of great interest, with 2 classes of drugs, fibric acid derivatives and nicotinic acid, and have mixed trial results when used on top of standard lipid therapy. However, a new class of medications, cholesteryl ester transfer protein inhibitors, has shown increases in HDL-C of over 100%. However, early trial results with torcetrapib showed an increase in mortality, although this was attributed to off-target toxicity. Dalcetrapib was found to be safer than torcetrapib, but data released in 2012 showed no additional benefit in patients suffering an acute coronary syndrome event. Two newer agents, anacetrapib and evacetrapib, in early-phase clinical trials have shown to be safer than torcetrapib and significantly more potent than dalcetrapib (both increase HDL-C by a greater amount and both have a significant effect on low-density lipoprotein cholesterol). It remains to be seen whether the use of cholesteryl ester transfer protein inhibitors will result in clinical benefit in large, randomized double-blind trials and whether any agents in this class will ever be approved for clinical use. Copyright © 2013 Wolters Kluwer Health, Inc. All rights reserved.
Summa Health System | Date: 2011-11-17
A method and system of transforming patient care including a multi-disciplinary strategy consisting of the adoption of a code alert used to mobilize and coordinate all treatment caregivers, improve regional paramedic education, and a database to track the progress of a patient as they move through the emergency medical system is described. In an effort to reduce the elapsed time from when the patient first encounters medical providers to the time of treatment, the time intervals during a patients treatment travel are tracked and analyzed to highlight areas that need to be improved upon.
Summa Health System | Date: 2013-11-08
Provided herein is a method of promoting wound healing in a subject, comprising administering to the subject vitamin C, vitamin K, a polyphenol, or a combination thereof. Also provided herein is a method of treating a wound in a subject, comprising administering to the subject vitamin C, vitamin K, a polyphenol, or a combination thereof.
Mayo Foundation For Medical Education And Research and Summa Health System | Date: 2015-04-08
Provided herein are methods for treating, preventing, or ameliorating one or more symptoms of a polycystic disease in a subject, comprising administering to the subject a therapeutically effective amount of vitamins C and K.
Summa Health System and Mayo Foundation For Medical Education And Research | Date: 2015-12-31
Provided herein is a pharmaceutical composition comprising vitamin C and chromium-free vitamin K, and optionally one or more pharmaceutically acceptable excipient(s). Also provided herein is a chromium-free pharmaceutical composition comprising vitamin C and vitamin K, and optionally one or more pharmaceutically acceptable excipient(s). Further provided herein is a method of treating, preventing, or managing an NFB-mediated condition, disorder, or disease, comprising administering to the subject a therapeutically effective amount of vitamin C and chromium-free vitamin K.